<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VANCOCIN- vancomycin hydrochlorideÂ capsuleÂ </strong><br>ViroPharma<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VANCOCIN CAPSULES safely and effectively. See full prescribing information for VANCOCIN CAPSULES. <br>VANCOCIN<span class="Sup">Â®</span> (vancomycin hydrochloride, USP) CAPSULES<br>Initial U.S. Approval: 1986
</div>
<div>
<div><p class="Highlighta">To reduce the development of drug-resistant bacteria and maintain the effectiveness of VANCOCIN CAPSULES and other antibacterial drugs, VANCOCIN CAPSULES should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.
  (<a href="#section-12.3">12.3</a>)</p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration (12/2011)
 </p>
<p class="Highlighta">Warnings and Precautions (12/2011)
 </p>
</div>
</div>
<div></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Treatment of:  (<a href="#s2">1</a>)
 </p>
<ul class="Disc">
<li>
<span class="Italics">C. difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">Enterocolitis</span> caused by <span class="Italics">Staphylococcus aureus</span> (including methicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)
</li>
</ul>
<p class="Highlighta">Important Limitations:  (<a href="#s2">1</a>) (<a href="#s10">5.1</a>)
 </p>
<ul class="Disc"><li>Orally administered VANCOCIN is not effective for other types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</li></ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">C. difficile-</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>:<ul class="Disc">
<li>Adult Patients (â‰¥18 years of age): 125 mg orally 4 times daily for 10 days.  (<a href="#s5">2.1</a>)
</li>
<li>Pediatric Patients (&lt;18 years of age): 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The total daily dosage should not exceed 2 g.  (<a href="#s6">2.2</a>)
</li>
</ul>
</li>
<li>Staphylococcal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>:<ul class="Disc">
<li>Adult Patients (â‰¥18 years of age): 500 mg to 2 g orally in 3 or 4 divided doses for 7 to 10 days.  (<a href="#s5">2.1</a>)
</li>
<li>Pediatric Patients (&lt;18 years of age): 40 mg/kg in 3 or 4 divided doses for 7 to 10 days. The total daily dosage should not exceed 2 g.  (<a href="#s6">2.2</a>)
</li>
</ul>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>125 mg capsules  (<a href="#s7">3</a>)
</li>
<li>250 mg capsules  (<a href="#s7">3</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to vancomycin (<a href="#s8">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">VANCOCIN must be given orally for treatment of staphylococcal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and
</span><span class="Bold Italics">C. difficile</span><span class="Bold">-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Orally administered VANCOCIN CAPSULES are not effective for other types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span>  (<a href="#s10">5.1</a>)
</li>
<li>Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of VANCOCIN for active <span class="Italics">C. difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  Monitoring of serum concentrations may be appropriate in some instances. (<a href="#s11">5.2</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> has occurred following oral VANCOCIN therapy and can occur either during or after completion of therapy. The risk is increased in geriatric patients (<a href="#s12">5.3</a>) Monitor renal function.
</li>
<li><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> has occurred in patients receiving VANCOCIN. (<a href="#s13">5.4</a>) Assessment of auditory function may be appropriate in some instances.
</li>
<li>Prescribing VANCOCIN in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. (<a href="#s15">5.6</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (â‰¥ 10%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (17%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (15%)<span class="Italics">,</span> and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (13%).  (<a href="#s17">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ViroPharma at (888-651-0201) or FDA at 1-800-FDA-1088 (</span><span class="Bold Italics">www.fda.gov/medwatch</span><span class="Bold">).</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">No drug interaction studies have been conducted.  (<a href="#s22">7</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Bold">Pediatrics:</span> Safety and effectiveness in patients &lt;18 years of age have not been established.  (<a href="#s27">8.4</a>)
</li>
<li>
<span class="Bold">Geriatrics:</span> In patients &gt;65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with VANCOCIN to detect potential vancomycin induced <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. (<a href="#s12">5.3</a>) (<a href="#s17">6.1</a>) (<a href="#s28">8.5</a>) (<a href="#s38">14.1</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-3" class="toc">2 Dosage and Administration
</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Adults
</a></h2>
<h2><a href="#section-3.2" class="toc">2.2 Pediatric Patients
</a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 Oral Use Only
</a></h2>
<h2><a href="#section-6.2" class="toc">5.2 Potential for Systemic Absorption
</a></h2>
<h2><a href="#section-6.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>
</a></h2>
<h2><a href="#section-6.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>
</a></h2>
<h2><a href="#section-6.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfection</span>
</a></h2>
<h2><a href="#section-6.6" class="toc">5.6 Development of Drug-Resistant Bacteria
</a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 Clinical Trial Experience
</a></h2>
<h2><a href="#section-7.2" class="toc">6.2 Postmarketing Experience
</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h2><a href="#section-12.3" class="toc">12.4 Microbiology
</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Associated with <span class="Italics">Clostridium difficile</span></a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">VANCOCIN</span><span class="Sup">Â®
</span><span class="Bold">(vancomycin hydrochloride, USP) CAPSULES</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">VANCOCIN CAPSULES are indicated for the treatment of <span class="Italics">C. difficil</span>e-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  VANCOCIN CAPSULES are also used for the treatment of <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> caused by <span class="Italics">Staphylococcus aureus</span> (including methicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).  Parenteral administration of vancomycin is not effective for the above <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; therefore, VANCOCIN CAPSULES must be given orally for these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold">Orally administered VANCOCIN is not effective for other types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of VANCOCIN CAPSULES and other antibacterial drugs, VANCOCIN CAPSULES should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>2 Dosage and Administration
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.1"></a><p></p>
<h2>2.1 Adults
</h2>
<p class="First">VANCOCIN CAPSULES are used in treating <span class="Italics">C. difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and staphylococcal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>.
</p>
<ul class="Disc">
<li>
<span class="Italics">C. difficile-</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: The recommended dose is 125 mg administered orally 4 times daily for 10 days.
</li>
<li>Staphylococcal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>: Total daily dosage is 500 mg to 2 g administered orally in 3 or 4 divided doses for 7 to 10 days.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-3.2"></a><p></p>
<h2>2.2 Pediatric Patients
</h2>
<p class="First">The usual daily dosage is 40 mg/kg in 3 or 4 divided doses for 7 to 10 days.  The total daily dosage should not exceed 2 g.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s7"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">VANCOCIN 125 mg* CAPSULES have an opaque blue cap and opaque brown body imprinted with â€œ3125â€? on the cap and â€œVANCOCIN HCL 125 MGâ€? on the body in white ink.
</p>
<p>VANCOCIN 250 mg* CAPSULES have an opaque blue cap and opaque lavender body imprinted with â€œ3126â€? on the cap and â€œVANCOCIN HCL 250 MGâ€? on the body in white ink.
</p>
<p>*Equivalent to vancomycin.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">VANCOCIN CAPSULES are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to vancomycin.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-6.1"></a><p></p>
<h2>5.1 Oral Use Only
</h2>
<p class="First"><span class="Bold">This preparation for the treatment of <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> is for oral use only and is not systemically absorbed.  VANCOCIN CAPSULES must be given orally for treatment of staphylococcal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and
</span><span class="Bold Italics">Clostridium difficile-</span><span class="Bold">associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Orally administered VANCOCIN CAPSULES are not effective for other types of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span></p>
<p><span class="Bold">Parenteral administration of vancomycin is
</span><span class="Bold Italics">not
</span><span class="Bold">effective for treatment of staphylococcal <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and
</span><span class="Bold Italics">C. difficile</span><span class="Bold">-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  If parenteral vancomycin therapy is desired, use an intravenous preparation of vancomycin and consult the package insert accompanying that preparation</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-6.2"></a><p></p>
<h2>5.2 Potential for Systemic Absorption
</h2>
<p class="First">Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of VANCOCIN for active <span class="Italics">C. difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Some patients with inflammatory disorders of the intestinal mucosa also may have significant systemic absorption of vancomycin.  These patients may be at risk for the development of adverse reactions associated with higher doses of VANCOCIN; therefore, monitoring of serum concentrations of vancomycin may be appropriate in some instances, e.g., in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and/or <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> or in those receiving concomitant therapy with an aminoglycoside antibiotic.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-6.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> (e.g., reports of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, blood creatinine increased) has occurred following oral VANCOCIN therapy in randomized controlled clinical studies, and can occur either during or after completion of therapy.  The risk of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> is increased in patients &gt;65 years of age (<span class="Italics">see ADVERSE REACTIONS, Clinical Trial Experience [<a href="#s17">6.1</a>] and USE IN SPECIFIC POPULATIONS, Geriatric Use [<a href="#s28">8.5</a>]</span>).
</p>
<p>In patients &gt;65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with VANCOCIN to detect potential vancomycin induced <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-6.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> has occurred in patients receiving vancomycin.  It may be transient or permanent.  It has been reported mostly in patients who have been given excessive intravenous doses, who have an underlying <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, or who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside.  Serial tests of auditory function may be helpful in order to minimize the risk of <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">ototoxicity</span> (<span class="Italics">see ADVERSE REACTIONS, Postmarketing Experience [<a href="#s18">6.2</a>]</span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-6.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfection</span>
</h2>
<p class="First">Use of VANCOCIN may result in the overgrowth of nonsusceptible bacteria.  If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-6.6"></a><p></p>
<h2>5.6 Development of Drug-Resistant Bacteria
</h2>
<p class="First">Prescribing VANCOCIN in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s16"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-7.1"></a><p></p>
<h2>6.1 Clinical Trial Experience
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
</p>
<p>The data described below reflect exposure to VANCOCIN in 260 adult subjects in two Phase 3 clinical trials for the treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with <span class="Italics">C. difficile.</span>  In both trials, subjects received VANCOCIN 125 mg orally four times daily. The mean duration of treatment was 9.4 days. The median age of patients was 67, ranging between 19 and 96 years of age. Patients were predominantly Caucasian (93%) and 52% were male.
</p>
<p>Adverse reactions occurring in â‰¥ 5% of VANCOCIN-treated subjects are shown in <a href="#t1">Table 1</a>.  The most common adverse reactions associated with VANCOCIN (â‰¥ 10%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Common (â‰¥ 5%) Adverse Reactions<span class="Sup">a</span> for VANCOCIN Reported in Clinical Trials for Treatment of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Associated with C. difficile
</span></caption>
<col align="left" width="37.112%">
<col align="left" width="38.346%">
<col align="left" width="24.542%">
<tfoot><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span> Adverse reaction rates were derived from the incidence of treatment-emergent adverse events.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">System/Organ Class</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">VANCOCIN</span><br><span class="Bold">% (N=260)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">17<br>15<br>9<br>9<br>8<br><br>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">General disorders and administration site conditions</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span><br><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span><br><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">9<br>6<br>5
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and nutrition disorders</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">13
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td class="Botrule Rrule" align="center" valign="top">7<br>
</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> (e.g., reports of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, blood creatinine increased) occurred in 5% of subjects treated with VANCOCIN.  <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> following VANCOCIN typically first occurred within one week after completion of treatment (median day of onset was Day 16). <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> following VANCOCIN occurred in 6% of subjects &gt;65 years of age and 3% of subjects â‰¤65 years of age (<span class="Italics">see WARNINGS AND PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> [<a href="#s12">5.3</a>]</span>).
</p>
<p>The incidences of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> were higher among subjects &gt;65 years of age than in subjects â‰¤65 years of age (<span class="Italics">see USE IN SPECIFIC POPULATIONS, Geriatric Use [<a href="#s28">8.5</a>]</span>).
</p>
<p>Discontinuation of study drug due to adverse events occurred in 7% of subjects treated with VANCOCIN.  The most common adverse events leading to discontinuation of VANCOCIN were <span class="Italics">C. difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (&lt;1%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (&lt;1%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (&lt;1%).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-7.2"></a><p></p>
<h2>6.2 Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of VANCOCIN.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span></span>: Cases of <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> associated with intravenously administered vancomycin have been reported.  Most of these patients had <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">kidney dysfunction</span> or a preexisting <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> or were receiving concomitant treatment with an ototoxic drug (<span class="Italics">see WARNINGS AND PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> [<a href="#s13">5.4</a>]</span>). <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> have been reported.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Italics">Hematopoietic</span>:  Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, usually starting 1 week or more after onset of intravenous therapy with vancomycin or after a total dose of more than 25 g, has been reported for several dozen patients.  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> appears to be promptly reversible when vancomycin is discontinued.  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> has been reported.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-7.2.3"></a><p></p>
<p class="First"><span class="Italics">Miscellaneous</span>:  Patients have been reported to have had <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> (including <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and rare cases of <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> in association with the administration of vancomycin.
</p>
<p>A condition has been reported that is similar to the IVâ€“induced syndrome with symptoms consistent with <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the upper body (â€œRed Man Syndromeâ€?), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> of the chest and back.  These reactions usually resolve within 20 minutes but may persist for several hours.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s22"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First">No drug interaction studies have been conducted.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s23"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s24"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-9.1.1"></a><p></p>
<p class="First">Pregnancy Category B â€“ The highest doses of vancomycin tested were not teratogenic in rats given up to 200 mg/kg/day IV (1180 mg/m<span class="Sup">2</span> or 1 times the recommended maximum human dose based on body surface area) or in rabbits given up to 120 mg/kg/day IV (1320 mg/m<span class="Sup">2</span> or 1.1 times the recommended maximum human dose based body surface area). No effects on fetal weight or development were seen in rats at the highest dose tested or in rabbits given 80 mg/kg/day (880 mg/m<span class="Sup">2</span> or 0.74 times the recommended maximum human dose based on body surface area).
</p>
<p>In a controlled clinical study, the potential ototoxic and nephrotoxic effects of vancomycin on infants were evaluated when the drug was administered intravenously to pregnant women for serious <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span> complicating intravenous drug abuse.  Vancomycin was found in cord blood.  No <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">sensorineural hearing loss</span> or <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> attributable to vancomycin was noted.  One infant whose mother received vancomycin in the third trimester experienced <span class="product-label-link" type="condition" conceptid="377888" conceptname="Conductive hearing loss">conductive hearing loss</span> that was not attributed to the administration of vancomycin.  Because the number of subjects treated in this study was limited and vancomycin was administered only in the second and third trimesters, it is not known whether vancomycin causes fetal harm.  Because animal reproduction studies are not always predictive of human response, VANCOCIN should be given to a pregnant woman only if clearly needed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s26"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Vancomycin is excreted in human milk based on information obtained with the intravenous administration of vancomycin.  However, systemic absorption of vancomycin is very low following oral administration of VANCOCIN <span class="Italics">(see CLINICAL PHARMACOLOGY, Pharmacokinetics [<a href="#s33">12.3</a>])</span>.  It is not known whether vancomycin is excreted in human milk, as no studies of vancomycin concentration in human milk after oral administration have been done.  Caution should be exercised when VANCOCIN is administered to a nursing woman.  Because of the potential for adverse events, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s27"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s28"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">In clinical trials, 54% of VANCOCIN-treated subjects were &gt;65 years of age.  Of these, 40% were between the ages of &gt;65 and 75, and 60% were &gt;75 years of age.
</p>
<p>Clinical studies with VANCOCIN in <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> associated with <span class="Italics">Clostridium difficile</span> have demonstrated that geriatric subjects are at increased risk of developing <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> following treatment with oral VANCOCIN, which may occur during or after completion of therapy.  In patients &gt;65 years of age, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with VANCOCIN to detect potential vancomycin induced <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> (<span class="Italics">see WARNINGS AND PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> [<a href="#s12">5.3</a>]; ADVERSE REACTIONS, Clinical Trial Experience [<a href="#s17">6.1</a>] and  CLINICAL STUDIES, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Associated with Clostridium difficile [<a href="#s38">14.1</a>])</span>.
</p>
<p>Patients &gt;65 years of age may take longer to respond to therapy compared to patients â‰¤65 years of age <span class="Italics">(see CLINICAL STUDIES, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Associated with Clostridium difficile [<a href="#s38">14.1</a>]).</span>  Clinicians should be aware of the importance of appropriate duration of VANCOCIN treatment in patients &gt;65 years of age andÂ not discontinue or switch to alternative treatment prematurely.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s29"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">Supportive care is advised, with maintenance of glomerular filtration.  Vancomycin is poorly removed by dialysis.  Hemofiltration and hemoperfusion with polysulfone resin have been reported to result in increased vancomycin clearance.
</p>
<p>To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center.  Telephone numbers of certified poison control centers are listed in the <span class="Italics">Physicians' Desk Reference (PDR)</span>.  In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s30"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">VANCOCIN CAPSULES for oral administration contain chromatographically purified vancomycin hydrochloride, a tricyclic glycopeptide antibiotic derived from <span class="Italics">Amycolatopsis orientalis</span> (formerly <span class="Italics">Nocardia orientalis</span>), which has the chemical formula C<span class="Sub">66</span>H<span class="Sub">75</span>Cl<span class="Sub">2</span>N<span class="Sub">9</span>O<span class="Sub">24</span>â€¢HCl.  The molecular weight of vancomycin hydrochloride is 1485.73; 500 mg of the base is equivalent to 0.34 mmol.
</p>
<p>The capsules contain vancomycin hydrochloride equivalent to 125 mg (0.08 mmol) or 250 mg (0.17 mmol) vancomycin.  The capsules also contain F D &amp; C Blue No. 2, gelatin, iron oxide, polyethylene glycol, titanium dioxide, and other inactive ingredients.
</p>
<p>Vancomycin hydrochloride has the structural formula:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7f386c7-8b78-4751-b6ae-e171925c2d54&amp;name=van00-0008-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s31"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s32"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Vancomycin is an antibacterial drug (<span class="Italics">see CLINICAL PHARMACOLOGY, Microbiology [<a href="#s34">12.4</a>]</span>).
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s33"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Vancomycin is poorly absorbed after oral administration.  During multiple dosing of 250 mg every 8 hours for 7 doses, fecal concentrations of vancomycin in volunteers exceeded 100 mg/kg in the majority of samples.  No blood concentrations were detected and urinary recovery did not exceed 0.76%.  In anephric subjects with no <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> who received vancomycin oral solution 2 g for 16 days, blood concentrations of vancomycin were less than or equal to 0.66 Î¼g/mL in 2 of 5 subjects. No measurable blood concentrations were attained in the other 3 subjects. Following doses of 2 g daily, concentrations of drug were &gt;3100 mg/kg in the feces and &lt;1 Î¼g/mL in the serum of subjects with normal renal function who had <span class="Italics">C. difficile-</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.  After multiple-dose oral administration of vancomycin, measurable serum concentrations may occur in patients with active <span class="Italics">C. difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and, in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the possibility of accumulation exists. It should be noted that the total systemic and renal clearances of vancomycin are reduced in the elderly (<span class="Italics">see USE IN SPECIFIC POPULATIONS, Geriatric Use [<a href="#s28">8.5</a>]</span>).
</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s34"></a><a name="section-12.3"></a><p></p>
<h2>12.4 Microbiology
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="e34"></a><a name="section-12.3.1"></a><p></p>
<p class="First">Mechanism of action
</p>
<p>The bactericidal action of vancomycin against <span class="Italics">Staphylococcus aureus</span> and the vegetative cells of <span class="Italics">Clostridium difficile</span> results primarily from inhibition of cell-wall biosynthesis.  In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e35"></a><a name="section-12.3.2"></a><p></p>
<p class="First">Mechanism of resistance
</p>
<dl>
<dt>Â 
</dt>
<dd><span class="Italics">Staphylococcus aureus</span></dd>
<dt>Â 
</dt>
<dd>
<span class="Italics">S. aureus</span> isolates with vancomycin minimal inhibitory concentrations (MICs) as high as 1024 mcg/mL have been reported.
</dd>
<dt>Â 
</dt>
<dd>The exact mechanism of this resistance is not clear but is believed to be due to cell wall thickening and potentially the transfer of genetic material.
</dd>
<dt>Â 
</dt>
<dd><span class="Italics">Clostridium difficile</span></dd>
<dt>Â 
</dt>
<dd>Isolates of <span class="Italics">C. difficile</span> generally have vancomycin MICs of &lt;1 mcg/mL, however vancomycin MICs ranging from 4 mcg/mL to 16 mcg/mL have been reported. The mechanism which mediates <span class="Italics">C. difficile's</span> decreased susceptibility to vancomycin has not been fully elucidated.
</dd>
</dl>
<p>Vancomycin has been shown to be active against susceptible isolates of the following bacteria in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section.
</p>
<p>Gram-positive bacteria
</p>
<dl>
<dt>Â 
</dt>
<dd>
<span class="Italics">Staphylococcus aureus</span> (including methicillin-resistant isolates<span class="Italics">)</span> associated with <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>
</dd>
</dl>
<p>Anaerobic Gram-positive bacteria
</p>
<dl>
<dt>Â 
</dt>
<dd>
<span class="Italics">Clostridium difficile</span> isolates associated with C. difficile associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.
</dd>
</dl>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s35"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s36"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">No long-term carcinogenesis studies in animals have been conducted.
</p>
<p>At concentrations up to 1000 Î¼g/mL, vancomycin had no mutagenic effect <span class="Italics">in vitro</span> in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay or the primary rat hepatocyte unscheduled DNA synthesis assay.  The concentrations tested <span class="Italics">in vitro</span> were above the peak plasma vancomycin concentrations of 20 to 40 Î¼g/mL usually achieved in humans after slow infusion of the maximum recommended dose of 1 g.  Vancomycin had no mutagenic effect <span class="Italics">in vivo</span> in the Chinese hamster sister chromatid exchange assay (400 mg/kg IP) or the mouse micronucleus assay (800 mg/kg IP).
</p>
<p>No definitive fertility studies have been conducted.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s37"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Associated with <span class="Italics">Clostridium difficile</span>
</h2>
<p class="First">In two trials, VANCOCIN 125 mg orally four times daily for 10 days was evaluated in 266 adult subjects with <span class="Italics">C. difficile</span>-associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD).  Enrolled subjects were 18 years of age or older and received no more than 48 hours of treatment with oral VANCOCIN or oral/intravenous metronidazole in the 5 days preceding enrollment.  CDAD was defined as â‰¥3 loose or watery bowel movements within the 24 hours preceding enrollment, and the presence of either <span class="Italics">C. difficile</span> toxin A or B, or pseudomembranes on endoscopy within the 72 hours preceding enrollment. Subjects with fulminant <span class="Italics">C. difficile</span> disease, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, peritoneal signs or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> were excluded.
</p>
<p>Efficacy analyses were performed on the Full Analysis Set (FAS), which included randomized subjects who received at least one dose of VANCOCIN and had any post-dosing investigator evaluation data (N=259; 134 in Trial 1 and 125 in Trial 2).
</p>
<p>The demographic profile and baseline CDAD characteristics of enrolled subjects were similar in the two trials. VANCOCIN-treated subjects had a median age of 67 years, were mainly white (93%), and male (52%). CDAD was classified as severe (defined as 10 or more unformed bowel movements per day or WBC â‰¥15000/mm<span class="Sup">3</span>) in 25% of subjects, and 47% were previously treated for CDAD.
</p>
<p>Efficacy was assessed by using clinical success, defined as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolution and the absence of severe <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> due to CDAD, on Day 10. An additional efficacy endpoint was the time to resolution of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, defined as the beginning of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolution that was sustained through the end of the prescribed active treatment period.
</p>
<p>The results for clinical success for VANCOCIN-treated subjects in both trials are shown in <a href="#t2">Table 2</a>.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2:  Clinical Success Rates (Full Analysis Set)
</span></caption>
<col align="left" width="21.733%">
<col align="left" width="40.567%">
<col align="left" width="37.700%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Clinical Success Rate</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">95% Confidence Interval</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">VANCOCIN % (N)</span></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Trial 1</span></td>
<td class="Botrule Rrule" align="center" valign="top">81.3 (134)
</td>
<td class="Botrule Rrule" align="center" valign="top">(74.4, 88.3)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Trial 2</span></td>
<td class="Botrule Rrule" align="center" valign="top">80.8 (125)
</td>
<td class="Botrule Rrule" align="center" valign="top">(73.5, 88.1)
</td>
</tr>
</tbody>
</table>
<p>The median time to resolution of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was 5 days and 4 days in Trial 1 and Trial 2, respectively.  For subjects older than 65 years of age, the median time to resolution was 6 days and 4 days in Trial 1 and Trial 2, respectively.  In subjects with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolution at end-of-treatment with VANCOCIN, recurrence of CDAD during the following four weeks occurred in 25 of 107 (23%) and 18 of 102 (18%) in Trial 1 and Trial 2, respectively.
</p>
<p>Restriction Endonuclease Analysis (REA) was used to identify <span class="Italics">C. difficile</span> baseline isolates in the BI group. In Trial 1, the Vancocin-treated subjects were classified at baseline as follows 31 (23%) with BI <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, 69 (52%) with non-BI <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, and 34 (25%) with unknown <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.Â  Clinical success rates were 87% forÂ BI <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, 81% for non-BI <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, and 76% for unknown <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.Â  In subjects with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> resolution at end-of treatment with VANCOCIN, recurrence of CDAD during the following four weeks occurred in 7 of 26 subjects with BI <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, 12 of 56 subjects with non-BI <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>, and 6 of 25 subjects with unknown <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s39"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">VANCOCIN CAPSULES are available in:
</p>
<p>The 125 mg* capsules have an opaque blue cap and opaque brown body imprinted with â€œ3125â€? on the cap and â€œVANCOCIN HCL 125 MGâ€? on the body in white ink.Â  A carton contains 2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs.  Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack contains 10 capsules for a total of 20 capsules per carton.Â  NDC 66593-3125-2 (PU3125)
</p>
<p>The 250 mg* capsules have an opaque blue cap and opaque lavender body imprinted with â€œ3126â€? on the cap and â€œVANCOCIN HCL 250 MGâ€? on the body in white ink.Â  A carton contains 2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs.  Each <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack contains 10 capsules for a total ofÂ 20 capsules per carton.Â NDC 66593-3126-2 (PU3126)
</p>
<p>Store at controlled room temperature, 59Â° to 86Â°F (15Â° to 30Â°C).
</p>
<p>*Equivalent to vancomycin.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s40"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Patients should be counseled that antibacterial drugs including VANCOCIN should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When VANCOCIN is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by VANCOCIN or other antibacterial drugs in the future.
</p>
<p>________________________________________________________________________
</p>
<p>VANCOCIN<span class="Sup">Â®</span> is a registered U.S. trademark owned by ViroPharma Incorporated.
</p>
<p>Rx Only<br>Â© ViroPharma Incorporated 2005. All rights reserved.<br>Distributed by: ViroPharma Incorporated, Exton, PA 19341, USA
</p>
<p>Rev. 12/2011
</p>
<p><span class="Bold">VIROPHARMA</span><span class="Sup">Â®</span><br>INCORPORATED
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s100"></a><a name="section-17"></a><p></p>
<p class="First">
<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Label 125 mg
</p>
<p><span class="Bold">
VACNOCIN</span><span class="Sup">Â®</span><span class="Bold">HCI</span></p>
<p>
vancomycin hydrochloride
</p>
<p>
Equiv. to 
<span class="Bold">
125 mg
</span>
 vancomycin
</p>
<div class="Figure">
<a name="f02"></a><img alt="<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7f386c7-8b78-4751-b6ae-e171925c2d54&amp;name=van00-0008-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s102"></a><a name="section-18"></a><p></p>
<p class="First">
Carton Label 125 mg
</p>
<p>
Equiv. to 
<span class="Bold">
125 mg
</span>
 vancomycin
</p>
<p><span class="Bold">
VACNOCIN</span><span class="Sup">Â®</span></p>
<p><span class="Bold">
(vancomycin hydrochloride capsules, USP)
</span></p>
<p><span class="Bold">
Rx only
</span></p>
<p>
Not a Child Resistant Container
</p>
<p><span class="Bold">
20 CAPSULES No. 3125
</span></p>
<p>
NDC 66593-3125-2 (125mg)
</p>
<p>
VIROPHARMA<span class="Sup">Â®</span></p>
<p>
INCORPORATED
</p>
<div class="Figure">
<a name="f03"></a><img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7f386c7-8b78-4751-b6ae-e171925c2d54&amp;name=van00-0008-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s103"></a><a name="section-19"></a><p></p>
<p class="First">
<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Label 250 mg
</p>
<p><span class="Bold">
VACNOCIN</span><span class="Sup">Â®</span><span class="Bold">HCI
</span></p>
<p>
vancomycin hydrochloride
</p>
<p>
Equiv. to 
<span class="Bold">
250 mg
</span>
 vancomycin
</p>
<div class="Figure">
<a name="f04"></a><img alt="<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7f386c7-8b78-4751-b6ae-e171925c2d54&amp;name=van00-0008-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s104"></a><a name="section-20"></a><p></p>
<p class="First">
Carton Label 250 mg
</p>
<p>
Equiv. to 
<span class="Bold">
250 mg
</span>
 vancomycin
</p>
<p><span class="Bold">
VACNOCIN</span><span class="Sup">Â®</span></p>
<p><span class="Bold">
(vancomycin hydrochloride capsules, USP)
</span></p>
<p><span class="Bold">
Rx only
</span></p>
<p>
Not a Child Resistant Container
</p>
<p><span class="Bold">
20 CAPSULES No. 3125
</span></p>
<p>
NDC 66593-3126-2 (250mg)
</p>
<p>
VIROPHARMA<span class="Sup">Â®</span></p>
<p>
INCORPORATED
</p>
<div class="Figure">
<a name="f05"></a><img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b7f386c7-8b78-4751-b6ae-e171925c2d54&amp;name=van00-0008-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VANCOCINÂ 		
					</strong><br><span class="contentTableReg">vancomycin hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66593-3125</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>vancomycin hydrochloride</strong> (vancomycin) </td>
<td class="formItem">vancomycin</td>
<td class="formItem">125Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Ferric Oxide Red</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Ferric Oxide Yellow</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue) ,Â BROWN (brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">3125
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66593-3125-2</td>
<td class="formItem">2  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050606</td>
<td class="formItem">04/15/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VANCOCINÂ 		
					</strong><br><span class="contentTableReg">vancomycin hydrochloride capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66593-3126</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>vancomycin hydrochloride</strong> (vancomycin) </td>
<td class="formItem">vancomycin</td>
<td class="formItem">250Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Blue NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Ferric Oxide Red</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Ferrosoferric Oxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue) ,Â PURPLE (lavender) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">3126
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66593-3126-2</td>
<td class="formItem">2  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050606</td>
<td class="formItem">04/15/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>ViroPharma
							(928902857)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Norwich Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">132218731</td>
<td class="formItem">MANUFACTURE(66593-3125, 66593-3126)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Axellia Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">305814345</td>
<td class="formItem">API MANUFACTURE(66593-3125, 66593-3126)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a8e22fc7-9201-471f-aa68-808a7fe3978b</div>
<div>Set id: b7f386c7-8b78-4751-b6ae-e171925c2d54</div>
<div>Version: 9</div>
<div>Effective Time: 20111213</div>
</div>
</div>Â <div class="DistributorName">ViroPharma</div></p>
</body></html>
